eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

Press/Media

Period	26 Oct 2022

Media coverage

Title	eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Media name/outlet	BioSpace
Country/Territory	United States
Date	26/10/22
URL	https://www.biospace.com/article/releases/effector-therapeutics-completes-enrollment-in-second-of-three-cohorts-of-phase-1b-clinical-trial-of-zotatifin-for-the-treatment-of-covid-19/?s=95
Persons	Nevan Krogan